Nesiritide compared with milrinone for cardiac surgery.
Management of patients with low cardiac output syndromes is difficult. Current therapies (ie, inotropes) have associated adverse effects and have not been shown to impact clinical outcomes such as decreased mortality or length of stay. Patients unable to recover from low cardiac output states have end organ damage, increased lengths of stay, increased hospital costs, and readmissions. Nesiritide has been suggested as an alternative or adjunct medication to treat cardiac surgery patients. Recent trials have provided information on the effects of some of these agents on clinical outcomes including respiratory failure, length of stay, and mortality.
Blais
Danielle M
DM
Department of Pharmacy, The Ohio State University Medical Center, Columbus, OH 43210, USA. danielle.blais@osumc.edu
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D002303:Cardiac Output, Low / Q000188:drug therapy*; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D006801:Humans; D020105:Milrinone / Q000627:therapeutic use*; D045283:Natriuretic Agents / Q000627:therapeutic use; D020097:Natriuretic Peptide, Brain / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D018570:Risk Assessment; D013903:Thoracic Surgery
D045283:Natriuretic Agents; D010726:Phosphodiesterase Inhibitors; D020097:Natriuretic Peptide, Brain; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D020105:Milrinone